Provided by Tiger Trade Technology Pte. Ltd.

Inhibikase Therapeutics, Inc.

1.54
+0.01500.98%
Post-market: 1.540.00000.00%17:33 EST
Volume:642.19K
Turnover:981.28K
Market Cap:186.34M
PE:-2.76
High:1.56
Open:1.55
Low:1.50
Close:1.53
52wk High:4.20
52wk Low:1.33
Shares:121.00M
Float Shares:71.11M
Volume Ratio:2.45
T/O Rate:0.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5579
EPS(LYR):-1.1606
ROE:-131.71%
ROA:-79.11%
PB:2.56
PE(LYR):-1.33

Loading ...

Inhibikase Therapeutics Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
Dec 11

Cantor Fitzgerald Initiates Inhibikase Therapeutics With Overweight Rating, $4 Price Target

MT Newswires Live
·
Dec 11

Inhibikase Therapeutics Reports Q3 2025 Financials and Progress

TIPRANKS
·
Nov 25

Sands Capital Life Sciences Pulse Fund II Reports Acquisition of Inhibikase Therapeutics Common Shares

Reuters
·
Nov 25

Inhibikase Therapeutics Announces $93.6 Million Stock Offering

TIPRANKS
·
Nov 22

Inhibikase Therapeutics Shares up 7.2% Premarket After Co Advances Experimental Pulmonary Arterial Hypertension Drug to Late-Stage Study

THOMSON REUTERS
·
Nov 21

Inhibikase Therapeutics 46.1M share Spot Secondary priced at $1.45

TIPRANKS
·
Nov 21

BRIEF-Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share

Reuters
·
Nov 21

Inhibikase Therapeutics Inc - Prices Public Offering of 46 Mln Shares at $1.45 per Share

THOMSON REUTERS
·
Nov 21

Inhibikase Therapeutics Advances IKT-001 to Phase 3 Study

TIPRANKS
·
Nov 21

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire
·
Nov 21

Inhibikase Therapeutics to advance IKT-001 to Phase 3 clinical study in PAH

TIPRANKS
·
Nov 21

Inhibikase Therapeutics Inc - Improve-Pah Phase 3 Study Expected to Start in Q1 2026

THOMSON REUTERS
·
Nov 21

Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension

GlobeNewswire
·
Nov 21

Inhibikase Therapeutics: Strategic Advancements and Financial Strength Justify Buy Rating

TIPRANKS
·
Nov 19

Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens

Reuters
·
Nov 15

Inhibikase Therapeutics Q3 EPS $(0.13), Inline

Benzinga
·
Nov 15

Press Release: Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity

Dow Jones
·
Nov 15

Inhibikase Therapeutics Appoints Timothy Pigot as Chief Commercial and Strategy Officer to Bolster Leadership Team

Reuters
·
Aug 19

Inhibikase Therapeutics Strengthens Leadership Team With Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

THOMSON REUTERS
·
Aug 19